Compare Johnson & Johnson (JNJ) vs Toast Inc. Class A Common Stock (TOST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Toast Inc. Class A Common Stock — how do they compare? Johnson & Johnson trades at $257.71 (market cap $611.90B), while Toast Inc. Class A Common Stock trades at $30 (market cap $17.25B). The key difference: Johnson & Johnson is far larger — about 35.5× Toast Inc. Class A Common Stock's market cap, and Johnson & Johnson pays a 2.11% dividend while Toast Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Toast Inc. Class A Common Stock for 0 Days on average.
| JNJ | TOST | |
|---|---|---|
Market Cap | $611.90B | $17.25B |
Volume | 9,651,904 | 10,274,535 |
Sector | Health | Technology |
52-Week High | $278.43 | $39.02 |
52-Week Low | $186.00 | $22.33 |
Typical Hold Time | 129 Days | 0 Days |
Enterprise Value | $640.18B | $15.50B |
Dividend Yield | 2.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $248.61, down 5.73% in the last session, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q3 2026 earnings, beating estimates with $2.59 EPS versus $2.52 expected, continuing a trend of three consecutive quarterly beats. JNJ maintains robust profitability with 67.91% gross margins and 21.48% net income margins, supported by $94.19B in 2025 revenue and $26.80B net income.
Analyst consensus remains positive with 52.5% buy ratings and a $282.53 price target, representing 13.6% upside potential. Key risks include patent cliffs affecting pharmaceutical revenue and increasing debt-to-asset ratio reaching 24.06% in 2025. The company's diversified healthcare portfolio and strong dividend history provide stability, while new drug launches like Icotyde offer growth catalysts.
Toast (TOST) trades at $30.89, down 1.37% on the day, with neutral technical indicators showing support at $30 and resistance at $32. The company demonstrates strong fundamental performance with 23% revenue growth in Q2 2026 to $1.91B and expanding profit margins, though valuation metrics remain elevated with a P/E of 39.1. Recent expansion into convenience stores with Toast Fuel and AI-driven product enhancements signal continued growth initiatives.
The outlook remains positive with 61.8% analyst buy ratings and a $38.22 consensus price target representing 24% upside potential. Key risks include execution challenges in new market segments and competitive pressures in the restaurant technology space, while strong earnings beats and institutional support provide confidence in the growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Toast Inc. Class A Common Stock
Toast Inc. provides a cloud-based technology platform for the restaurant industry, combining point-of-sale hardware and software with payment processing, online ordering, payroll, and supplier management tools. The platform serves restaurants ranging from single locations to multi-unit groups across US.
Read more on TOST →
